Latest Compliance News

Australian Bond Exchange Holdings has entered a strategic Liquidity Provision Agreement with ViewTrade Australia, aiming to broaden investor access to OTC securities globally through integrated technology and expanded market channels.

Mont Royal Resources has voluntarily suspended its shares on the ASX pending a critical announcement about a proposed re-compliance transaction, signaling a pivotal moment for the mining company.

Perpetual Limited has received updated, non-binding proposals from KKR for its Wealth Management and Corporate Trust businesses, but key terms and shareholder proceeds remain uncertain.

Pengana International Equities Limited reported a striking 189% increase in net profit for the half-year ended December 31, 2024, alongside an 11% portfolio return and consistent fully franked dividends.

Lithium Universe Limited’s Definitive Feasibility Study confirms the economic viability of its Bécancour Lithium Refinery, projecting robust returns even amid subdued lithium prices. The project aims to produce 18,270 tonnes per year of battery-grade lithium carbonate, leveraging proven Jiangsu technology and a counter-cyclical development strategy.

Rox Resources reports compelling assay results from its 35,000m drilling campaign at Youanmi, alongside advancing metallurgical testing and critical infrastructure upgrades, positioning the project firmly on track for its mid-2025 resource update.

Artemis Resources has clarified the permitting status of its Radio Hill processing plant and outlined the regulatory and operational steps required to resume processing activities, while granting Greentech Metals an exclusive option to assess copper ore feasibility.

Triangle Energy reports a missed payment from Pilot Energy related to the Cliff Head project sale, while Pilot continues funding operational costs amid capital raise talks.

Acorn Capital Investment Fund Limited has been suspended from ASX trading due to a delayed periodic report, raising questions about its compliance and investor transparency.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Bendigo and Adelaide Bank has released its Basel III Pillar 3 disclosures for the year ended December 31, 2024, revealing solid capital adequacy and liquidity positions under APRA regulations. The bank maintains robust buffers amid lending growth and evolving market conditions.

GPT Group has confirmed a fully unfranked ordinary dividend of AUD 0.12 per security for the six months ending December 2024, payable on February 28, 2025.